Skip to main content

Firazyr Side Effects

Generic name: icatibant

Medically reviewed by Philip Thornton, DipPharm. Last updated on Aug 10, 2022.

Note: This document contains side effect information about icatibant. Some dosage forms listed on this page may not apply to the brand name Firazyr.


Common side effects of Firazyr include: hematoma at injection site, injection site reaction, urticaria at injection site, bruising at injection site, burning sensation at injection site, erythema at injection site, irritation at injection site, pain at injection site, and swelling at injection site. Continue reading for a comprehensive list of adverse effects.

Applies to icatibant: subcutaneous solution.

Serious side effects of Firazyr

Along with its needed effects, icatibant (the active ingredient contained in Firazyr) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking icatibant:

Less common

  • Fever

Other side effects of Firazyr

Some side effects of icatibant may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

Less common

Incidence not known

For Healthcare Professionals

Applies to icatibant: subcutaneous solution.


The most common adverse reactions were injection site reactions, pyrexia, transaminase increased, dizziness, and rash.[Ref]


Very common (10% or more): Injection site reaction (97%)[Ref]

Injection site reaction includes bruising, hematoma, burning, erythema, hypoesthesia, irritation, numbness, edema, pain, pressure sensation, pruritus, swelling, urticaria, or warmth at the site of injection.[Ref]


Common (1% to 10%): Rash, pruritus, erythema

Uncommon (0.1% to 1%): Generalized urticaria[Ref]


Common (1% to 10%): Nasopharyngitis, nasal congestion

Uncommon (0.1% to 1%): Pharyngitis, asthma, cough[Ref]


Common (1% to 10%): Gastroenteritis, nausea

Uncommon (0.1% to 1%): Vomiting[Ref]

Nervous system

Common (1% to 10%): Dizziness, headache[Ref]


Common (1% to 10%): Pyrexia

Uncommon (0.1% to 1%): Asthenia, fatigue, contusion[Ref]


Common (1% to 10%): Transaminase increased

Uncommon (0.1% to 1%): Liver function test abnormal[Ref]


Common (1% to 10%): Prothrombin time prolonged[Ref]


Common (1% to 10%): Blood creatinine phosphokinase increased[Ref]


Uncommon (0.1% to 1%): Weight increased, blood glucose increased, hyperuricemia, hyperglycemia[Ref]


Uncommon (0.1% to 1%): Herpes zoster

Frequency not reported: Anti-icatibant (the active ingredient contained in Firazyr) antibodies[Ref]


Uncommon (0.1% to 1%): Hot flush[Ref]


Uncommon (0.1% to 1%): Proteinuria[Ref]


Uncommon (0.1% to 1%): Muscle spasm[Ref]

Frequently asked questions


1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. "Product Information. Firazyr (icatibant)." Shire US Inc (2011):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.